Beranda › Penyakit Autoimun › Pennsylvania
Uji klinis Penyakit Autoimun di Pennsylvania
21 studi untuk Penyakit Autoimun mencari peserta di lokasi di Pennsylvania.
Kota di Pennsylvania
Teks studi resmi (Bahasa Inggris)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UPMC Hillman Cancer Center, Pittsburgh
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06722235A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
Menerima pesertaFase 2
Usia 16 hingga 70 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07328581RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients, Philadelphia
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients, Pittsburgh
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients, Pittsburgh
Menerima pesertaFase 2/3
Usia 6 hingga 75 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07103746A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Philadelphia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 1/2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06121297Abatacept for the Treatment of Giant Cell Arteritis
- University of Pennsylvania, Philadelphia
Menerima pesertaFase 3
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT04474847A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- The Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06056297KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Thomas Jefferson University Hospital, Philadelphia
Menerima pesertaFase 2/3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- dan 3 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- University of Pennsylvania, Philadelphia
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT04422912A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
Menerima pesertaFase 1
Usia 12 hingga 70 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT06308978Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting
- Magee-Womens Hospital, Pittsburgh
Menerima peserta
Semua usia · Pria · Diperbarui 22 Apr 2026 · NCT04452305Testicular Tissue Cryopreservation for Fertility Preservation
- Magee-Womens Hospital, Pittsburgh
Menerima peserta
Semua usia · Pria · Diperbarui 22 Apr 2026 · NCT02972801Ovarian Tissue Cryopreservation for Fertility Preservation
- Magee-Womens Hospital, Pittsburgh
Menerima pesertaStudi observasional
Hingga usia 39 · Wanita · Diperbarui 4 Mar 2026 · NCT05875155A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Temple University Hospital, Philadelphia
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Feb 2026 · NCT06626919Central Vein Sign in Multiple Sclerosis Extension Study
- University of Pennsylvania, Philadelphia
Menerima peserta
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 20 Feb 2026 · NCT07424027Autoimmunity After Checkpoint Blockade
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jan 2026 · NCT04119713X-linked Moesin Associated Immunodeficiency
- Perelman School of medecine, Philadelphia
Menerima pesertaStudi observasional
Usia 4 hingga 80 · Pria · Diperbarui 25 Apr 2025 · NCT06278337Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.